Commence introduces Amplify for health data management
Amplify aims to address the root causes of fragmented health data workflows by using AI and a data-first strategy, enabling agencies to optimise clinical reviews, automate processes, and quicken evidence-based results.
The solution offers a departure from the limitations of traditional systems by prioritising the understanding of unstructured medical content from the beginning.
This approach allows for the elimination of siloed intake models and fractured operations, providing agencies and enterprises with the capability to fully embrace automation, expedite decision-making, and enhance outcomes across essential programmes.
Commence chief growth officer Ian Checcio said: 'It's not about bolting on AI to a broken process; it's about starting with the data itself.
'Once you understand the flow of health content, you can enable AI to do its job: extract meaning, streamline action, and enhance meaningful outcomes.'
The platform handles operational obstacles by speeding up medical record retrieval, which reduces the time and effort required from providers and agencies.
It achieves this by automating and standardising intake in multiple channels.
The platform connects claims to clinical evidence for quality medical reviews and fraud detection. It also augments reviews with AI-driven tools.
Amplify supports benefit determinations and enhances case management by delivering structured data and AI-extracted insights directly into case workflows.
Using three integrated models, comprised of capture, review, and clarity, Amplify can function independently or in unison to ingest, interpret, and intelligently analyse health information.
The modules provide an adaptable, unified platform experience that caters to the varied challenges faced by healthcare and government entities.
Features of Amplify include unified data intake from various methods and modalities, noise reduction for data integrity, AI-ready processing for transforming unstructured documents, and dynamic case management.
Its capabilities also include AI-augmented medical reviews, natural language search, system interoperability with EHRs and claims systems, and end-to-end security that meets federal compliance standards.
Converting fragmented health records into intelligent and structured insights, Amplify improves government and healthcare programmes to lessen administrative burdens.
"Commence introduces Amplify for health data management" was originally created and published by Hospital Management, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
If You'd Invested $10,000 in Nvidia Stock 5 Years Ago, Here's How Much You'd Have Today
Key Points Nvidia's GPU technologies have been at the center of the AI revolution over the last five years. The importance of Nvidia's processing hardware has meant that the company's shareholders have been richly rewarded. GPU hardware sales are a fantastic foundation for Nvidia, but the company is also exploring growth opportunities in other categories. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) has helped transform the world and absolutely crushed the market over the last five years. The rise of the company's graphics processing units (GPUs) as essential computational hardware for training and running artificial intelligence (AI) applications has helped power incredible sales and earnings growth, and investors who have taken a long-term-holding approach to the company have been richly rewarded. Over the last five years, Nvidia stock has delivered share price gains of roughly 1,500%. That means that a $10,000 investment in the company half a decade ago would now be worth roughly $160,000. The AI hardware leader has delivered incredible wins for long-term shareholders, and forthcoming chapters in its growth story seem to hold plenty of promise. Nvidia continues to dominate the AI hardware market When it comes to the key computational hardware at the heart of the artificial intelligence revolution, no company has a stronger position than Nvidia. The company's advanced GPUs and AI accelerators have been delivering performance that's significantly exceeding the competition and paving the way for the most important leaps forward in artificial intelligence. With the company's last quarterly report, revenue increased roughly 69% year over year to reach approximately $44.1 billion, and non-GAAP (adjusted) earnings per share rose approximately 33% compared to the prior-year period even in the face of some heavy investment in growth projects. Nvidia's leadership in AI computing technologies is opening the door for the company to potentially become a leader in areas such as processing as a service and robotics, and the tech leader's competitive advantages suggest it could continue serving up wins for patient shareholders. Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. If You'd Invested $10,000 in Nvidia Stock 5 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
OpenAI's GPT-5 is out. Here's what you need to know.
OpenAI's ( GTP-5 is officially available. The company's most advanced AI model yet, and available now at OpenAI says GPT-5 is a step up from its prior GPT models across a number of areas, including writing, coding, health knowledge, and more. According to CEO Sam Altman, GPT-5 is like speaking to a "legitimate PhD-level expert.' It's also, the company says, less prone to hallucinations than previous releases. The biggest change you'll notice when using GPT-5 is that it is the only model you can use. You'll no longer be able to use GPT-4o or any other GPT version. But OpenAI says you shouldn't be too concerned about that. That's because GPT-5 can automatically switch between providing quick, efficient answers to queries and taking time to reason longer over more complex questions, depending on how you ask them. It's a helpful feature, to be sure, since you don't have to take the time to decide whether you're using the right model for your particular ask. If you're a Plus or Team user, you also have the option of selecting GPT-5 Thinking as your base model. But free users are out of luck. When you run through your usage limit, ChatGPT will automatically switch to smaller, less resource-intensive GPT-5 models. According to OpenAI, GPT-5 offers enhanced writing skills that include more literary depth and rhythm. It can also help you translate information from things like complex medical reports into plain English, making them far easier to understand. Of course, the model isn't bulletproof, so you'll want to double-check any medical information and run it by your doctor before making any decisions. GPT-5 is also more adept at coding than earlier GPT models. It can put together things like basic games and apps with just a few prompts and details. And unlike previous versions of GPT, GPT-5 gives your apps a bit of stylistic flair, rather than making them feel dull and flat. That should prove helpful for the types of folks who are interested in 'vibe coding,' or writing software using natural language prompts rather than actual code. GPT-5 is also more personal thanks to its ability to connect to Google (GOOG, GOOGL) Calendar, Gmail, and Contacts. In one demo, OpenAI showed how GPT-5 can help pull together a schedule based on your calendar and travel information from your email. It's the kind of helpfulness that is certain to attract some users, while turning off others who prefer to keep their more sensitive data private and away from third-party apps. Importantly, OpenAI says GPT-5 is less sycophantic than its predecessors. The company originally released an update to GPT-4o in April but quickly pulled it back after the chatbot began being overly flattering to users. It also, the company said, was validating users' doubts, fueling anger, and urging impulsive actions. Reports indicate that some users can experience emotional spirals when interacting with overly sycophantic bots. That should change with GPT-5. 'In targeted sycophancy evaluations using prompts specifically designed to elicit sycophantic responses, GPT‑5 meaningfully reduced sycophantic replies (from 14.5% to less than 6%),' the company said in its release announcing the new model. 'At times, reducing sycophancy can come with reductions in user satisfaction, but the improvements we made cut sycophancy by more than half while also delivering other measurable gains, so users continue to have high-quality, constructive conversations — in line with our goal to help people use ChatGPT well.' While GPT-5 is an important release, it won't put OpenAI in the AI driver's seat for long. Its competitors, including Anthropic ( Google, Meta (META), and Perplexity ( working on their own next-generation AI models. And in the ongoing tit-for-tat battle for AI supremacy, no company stays on top for long. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
A $10 Billion Reason to Buy Palantir Stock
Palantir Technologies (PLTR) is a leading software company that focuses on helping organizations make sense of large and complex data. Its platforms use advanced analytics and artificial intelligence to integrate various types of data, enabling customers, including government agencies and businesses in industries such as finance, healthcare, and energy, to gain simplified insights that facilitate better decision-making. Founded in 2003, the company is headquartered in Denver, Colorado. More News from Barchart Elon Musk Predicts Tesla Will 'Have Autonomous Ride-Hailing in Probably Half the Population of the US by the End of the Year' Should You Buy the 40% Post-Earnings Plunge in The Trade Desk Stock? Wedbush Thinks Palantir Is Speeding to $1 Trillion. Should You Buy PLTR Stock Now? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! About Palantir Stock Palantir's stock has been one of the standout performers in 2025, gaining more than 147% YTD, easily outpacing the benchmark S&P 500 Index's ($SPX) more modest 8.7% jump. The stock trades at its 52-week and all-time highs, having achieved nearly 550% growth over the past year. Moreover, it continues its rally with a 21.5% gain in five days and a 34% gain in a month. Palantir Posts Q2 Results Palantir posted its second-quarter results on Monday, Aug. 4. It reported adjusted earnings of $0.16 per share, beating analysts' $0.14 per share estimate, a significant 77% rise from the same quarter last year. The company also posted a record revenue figure, which stood at $1 billion, marking a 48% rise while surpassing estimates of $939 million. Palantir's U.S. commercial revenue jumped 93% to $306 million while U.S. government revenue rose 53% to $426 million. Beyond headline numbers, Palantir strengthened its financial position with record contract momentum: 157 contracts worth at least $1 million, 66 contracts worth at least $5 million, and 42 contracts of $10 million or more in Q2. Adjusted operating income hit $464 million, boosted by margin expansion to 46%, continuing an upward trend quarter-over-quarter. It had a free cash flow of $569 million with a 57% margin while cash reserves stood at $6 billion with zero debt. Looking ahead, Palantir raised its full-year 2025 revenue guidance to $4.142 billion to $4.15 billion, up from the previous forecast of $3.89 billion to $3.9 billion. The company also expects ongoing contract wins and growth in both government and commercial sectors, fueled by accelerating adoption of its Artificial Intelligence Platform and a recent multibillion-dollar U.S. Army contract. Palantir Wins U.S. Army Deal Palantir Technologies has secured a landmark contract with the U.S. Army valued at up to $10 billion over the next decade, marking the largest Department of Defense deal ever awarded to the company. The contract is a new enterprise agreement, which consolidates 75 existing contracts, including 15 prime contracts and 60 related ones, into a single streamlined contract intended to enhance military readiness and boost operational efficiency. The consolidation reduces procurement timelines, allowing soldiers quicker access to Palantir's advanced data integration, analytics, and AI tools. The deal also establishes volume-based discounts and provides the Army and other Department of Defense (DoD) entities flexibility to purchase Palantir's commercial products as needed, though total spending will not exceed the $10 billion cap. This contract significantly strengthens Palantir's role as a key technology provider for the military, while also driving cost savings and procurement simplification for the Army. Should You Buy Palantir? The stock has a consensus 'Hold' rating with a mean price target of $147.50 which is well below its trading price, but it is worth noting that Palantir trades at an all-time high with strong momentum that has analysts playing catch up with its performance. It has been rated by 21 analysts with four 'Strong Buy' ratings, 14 'Hold' ratings, one 'Moderate Sell' rating, and two 'Strong Sell' ratings. On the date of publication, Ruchi Gupta did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
